CN113694100B - Medicinal composition for treating chronic obstructive pulmonary disease and silicosis and application thereof - Google Patents
Medicinal composition for treating chronic obstructive pulmonary disease and silicosis and application thereof Download PDFInfo
- Publication number
- CN113694100B CN113694100B CN202111043663.8A CN202111043663A CN113694100B CN 113694100 B CN113694100 B CN 113694100B CN 202111043663 A CN202111043663 A CN 202111043663A CN 113694100 B CN113694100 B CN 113694100B
- Authority
- CN
- China
- Prior art keywords
- parts
- silicosis
- volatile oil
- herba
- medicinal composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/532—Agastache, e.g. giant hyssop
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Dispersion Chemistry (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Otolaryngology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a medicinal composition for treating chronic obstructive pulmonary disease and silicosis, which is prepared from the following raw materials in parts by weight: 4-14 parts of patchouli, 9-28 parts of rhizoma atractylodis, 5-18 parts of elsholtzia, 11-33 parts of folium artemisiae argyi, 0.1-3 parts of clove, 2-10 parts of mint and 0.01-0.2 part of natural borneol. The preparation method comprises the following steps: weighing the raw materials respectively, pulverizing herba Agastaches, rhizoma Atractylodis, herba Moslae, folium Artemisiae Argyi, flos Caryophylli and herba Menthae, performing supercritical carbon dioxide extraction, and separating to obtain herba Agastaches volatile oil, rhizoma Atractylodis volatile oil, herba Moslae volatile oil, folium Artemisiae Argyi volatile oil, flos Caryophylli volatile oil and herba Menthae volatile oil respectively, and mixing the volatile oils with natural Borneolum Syntheticum to obtain the medicinal composition. The medicinal composition for treating chronic obstructive pulmonary disease and silicosis has the advantages of short treatment course, quick response, thorough treatment, no toxic or side effect and low cost.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to a medicinal composition for treating chronic obstructive pulmonary diseases and silicosis and application thereof.
Background
The chronic obstructive pulmonary disease is chronic bronchitis and/or emphysema with airflow obstruction characteristics, can be further developed into common chronic diseases of pulmonary heart disease and respiratory failure, is related to abnormal inflammatory reaction of harmful gas and harmful particles, has high disability rate and death rate, and has the worldwide incidence rate of 9-10% above 40 years old. Chronic obstructive pulmonary disease is a common disease that can be prevented and treated characterized by persistent airflow limitation, which progresses in association with increased chronic inflammatory responses of the airways and lungs to toxic particles or gases. The exact cause of chronic obstructive pulmonary disease is not clear, and it is thought that factors involved in the development of both chronic bronchitis and obstructive emphysema may be involved in the onset of chronic obstructive pulmonary disease. Risk factors that have been found can be broadly divided into two categories, external (i.e., environmental factors) and internal (i.e., individual predisposition factors). Extrinsic factors include smoking, inhalation of dust and chemicals, air pollution, respiratory infections, and socioeconomic low (may be related to indoor and outdoor air pollution, crowding of the home, poor nutrition, and other factors associated with socioeconomic low status). Endogenous factors include genetic factors, increased airway responsiveness, individuals with lung development or poor growth during pregnancy, neonatal, infant or childhood due to a variety of causes.
Currently, current drug therapies can reduce or eliminate symptoms in patients, improve exercise endurance, reduce the number and severity of episodes to improve health status. Inhalation therapy is preferred, (1) bronchodilators clinically commonly used are of three classes, β 2 receptor agonists, cholinergic receptor blockers and methylxanthines, which act synergistically in combination. (2) Glucocorticoid inhalation has a history of repeated exacerbations and severe airway obstruction, and patients with FEV1<50% of expected values may inhale glucocorticoid. (3) Expectorant and antitussive expectorant are only used for sticky sputum with difficulty in cough, and are not recommended to be used regularly. (4) The antioxidant can thin sputum by using antioxidant such as N-acetylcysteine and carbocisteine, and can make the sputum easy to expectorate and reduce the frequency of repeated exacerbation of diseases.
Silicosis, also known as silicosis and silicosis, is a common type of pneumoconiosis. In professional activities, workers inhale dust with high content of free silica for a long time to cause pulmonary fibrosis characterized by double-lung diffuse nodular pulmonary fibrosis. The lung cancer can be divided into chronic lung cancer, acute lung cancer and acute lung cancer, wherein the chronic lung cancer is the most common and mainly shows cough, expectoration, chest distress, shortness of breath and the like, the diagnosis can be carried out through lung function examination and X-ray chest radiography, the early stage of the lung cancer can be complicated with diseases such as tuberculosis, lung infection, obstructive emphysema and the like if the lung cancer is not intervened, and the treatment of the lung cancer comprises symptomatic treatment, treatment of complications and drug treatment.
The prior art treatment methods have the following problems: the treatment time is long, the treatment is not thorough, some sequelae are left, the normal work and life of patients are affected, the treatment cost is high, and the toxic and side effects of different degrees are caused.
Therefore, the development of a pharmaceutical composition for treating chronic obstructive pulmonary disease and silicosis with short treatment course, quick response, thorough treatment, no toxic or side effect and low cost is a problem to be solved by the technical personnel in the field.
Disclosure of Invention
In view of the above, the present invention provides a pharmaceutical composition for treating chronic obstructive pulmonary disease and silicosis, and its application in preparing a medicament for treating chronic obstructive pulmonary disease and silicosis.
In order to achieve the purpose, the invention adopts the following technical scheme:
a medicinal composition for treating chronic obstructive pulmonary disease and silicosis comprises the following raw materials in parts by weight:
4-14 parts of patchouli, 9-28 parts of rhizoma atractylodis, 5-18 parts of elsholtzia, 11-33 parts of folium artemisiae argyi, 0.1-3 parts of clove, 2-10 parts of mint and 0.01-0.2 part of natural borneol.
The beneficial effects of the invention are: the medicinal composition for treating chronic obstructive pulmonary disease and silicosis has the effects of eliminating turbid pathogen with aromatics and freeing orifices, is used for treating light, common and convalescent coronary pneumonia and cold or influenza, and belongs to damp turbidity obstruction and stagnation of the lung in traditional Chinese medicine, and the symptoms of nasal obstruction, watery nasal discharge, cough, chest distress, short breath, fullness, weakness, muscle soreness, sore throat, sweating and the like are shown.
The formula mechanism is as follows:
1. the etiology of the major diseases
The main indications of the recipe are "light, common and convalescent coronary pneumonia" and "nasal obstruction, runny nose, cough, sore throat, etc. caused by cold or flu". Wherein, the new coronary pneumonia (2019-nCoV) belongs to the pestilence category with the nature of damp pathogen in traditional Chinese medicine, and the etiology attribute is the pathogenic factor of damp toxin. Dampness obstructing the spleen and lung, dysfunction of qi movement, transformation of damp-toxicity into heat, transmission of damp-toxin into yangming, formation of yangming fu-organ excess, retention of damp-toxicity and stagnant heat, deep and faint heat. The common cold or influenza can be caused by six exogenous pathogenic factors, namely wind-cold, summer-heat, dampness, and manic-fire, with both seasonal and non-seasonal qi.
2. The pathogenesis of the major diseases
According to the diagnosis and treatment scheme for pneumonia infected by novel coronavirus-trial seventh edition, the new coronary pneumonia has two types of mild symptoms of cold-damp stagnation lung syndrome and damp-heat accumulation lung syndrome; the common type of the new coronary pneumonia has two types of syndrome of stagnation of damp-toxin in the lung and syndrome of obstruction of cold-dampness in the lung; the convalescent stage of new coronary pneumonia has two types of lung-spleen qi deficiency and qi-yin deficiency. The pathogenesis of the new coronary pneumonia is characterized by 'dampness, toxicity, stasis and blockage', so the treatment always needs to be treated by dampness pathogen, and also relates to the deficiency aspect, the core pathogenesis is 'dampness, heat, toxicity, stasis and deficiency', and the whole course runs through dampness-toxicity lung, obstructed lung and blocked lung. Dampness is an important factor in new coronary pneumonia and runs through the whole course of the disease. The early symptoms are cold-dampness and damp-heat, and yang qi stagnation and heat transformation, damp-heat accumulation, middle energizer blockage, spleen and stomach ascending and descending influence, or damp-heat accumulation and up-flowing of damp-heat affecting the triple energizer to cause fever and sweating, chest distress and short breath, dizziness and hypodynamia, diarrhea and anorexia are easy to occur in the disease development process. According to the diagnosis and treatment scheme 2019 for influenza, the mild symptoms in traditional Chinese medicine are differentiated into two types of syndromes of wind-heat invading the wei and heat-toxin invading the lung. In conclusion, the mild and common type of Xinguan pneumonia, cold and influenza are mostly caused by the invasion of exogenous pathogenic factors into the lung, which affects the dysfunction of the lung and defense, resulting in disharmony between the defense and the exterior and failure of the lung to disperse and descend. The symptoms are aversion to cold, fever, nasal obstruction, running nose, cough, chest distress, fullness and the like. The excessive course of disease may cause spleen deficiency and lung deficiency.
3. Therapeutic methods for the treatment of diseases
According to the pathogenesis analysis result, treatment is carried out according to the treatment principle of 'dispersing lung qi and eliminating evil, eliminating dampness and strengthening spleen, and strengthening body resistance and eliminating evil'. For severe lung diseases, the lung can disperse lung qi, resolve dampness, induce heat, dissipate heat, and relieve cough and dyspnea if lung qi is normally dispersed and purified; for the spleen's weight regulating qi movement, it reaches the membrane origin, the spleen ascends the stomach and descends, the clear ascends and descends, so the damp pathogen is removed, the pivot reaches, and the triple energizer is harmonized smoothly. The royal jade light and the like classify and treat the novel coronavirus pneumonia into the category of 'damp-toxin plague', take the pathogenesis as the core, and adopt an early treatment method (which is equivalent to a light and common type of a novel coronavirus infection pneumonia diagnosis and treatment scheme-trial seventh edition) of keeping dirty and eliminating turbid, ventilating and smoothing lung and dispelling melancholy, and a recovery treatment method of clearing residual evil. In conclusion, for light-weight, common type and convalescent type of new coronary pneumonia and treatment of cold or influenza, it is advisable to eliminate turbid with aromatics and to disperse and dredge orifices.
4. Prescription analysis
In the formula, patchouli oil and rhizoma atractylodis oil are used as monarch drugs, elsholtzia oil, wormwood leaf oil, clove oil and peppermint oil are used as minister drugs, and natural borneol is used as adjuvant and guide drugs.
4.1 analysis of monarch drug
Pogostemon cablin (Blanco) Benth.]It is recorded in Ming Yi Bie Lu (miscellaneous records of famous physicians), with pungent and warm natures, entering spleen, stomach and lung meridians. Has the effects of eliminating turbid pathogen with aromatics, regulating the middle warmer, relieving vomit, relieving exterior syndrome and relieving summer heat. Can be used for treating damp turbidity obstruction in middle warmer, abdominal distention emesis, summer-heat dampness exterior syndrome, early stage of damp-warm syndrome, fever and listlessness, chest distress and discomfort, cold-dampness retention of summer-heat, abdominal pain, vomiting and diarrhea, nasosinusitis and headache. Its main role is to invigorate spleen with fragrance and transform damp-turbidity. Fragrant and pungent in flavor can disperse lung qi, help spleen to resolve dampness and remove stagnated heat. The book Bing Lu and the book Zhen Zhu Yao are loaded with the medicine for treating cholera, and the book Ben Cao (materia Medica entry and materia Medica) is loaded with the medicine for stopping malaria, wherein cholera and malaria are closely related to damp pathogen, the effects of dispelling cold and dampness, summer-heat and dampness, stagnated heat and damp-heat carried in the materia Medica and codling nature and the effects of purging the cold of lung pathogen and relieving the heat stagnation of chest and diaphragm carried in the materia Medica and codling nature are highlighted, namely, the effects of eliminating turbid with aromatics and relieving summer-heat are achieved. The Nile Zuo Hui Yan (the Chinese materia Medica) carries it: "it is special for removing foul smell". It is warm in nature, so it is the most rapid herb for people with damp-retention in spleen and yang, lassitude, weakness, lusterless diet and greasy tongue coating because it can dispel damp-turbidity and damp-evil and help spleen and stomach to strengthen qi. The recipe uses patchouli oil as medicine, and the patchouli oil has the functions of resisting bacteria, fungi, plasmodium and phytopathogen and regulating gastrointestinal movementHas pharmacological activities of promoting secretion of digestive juice, protecting intestinal barrier function, regulating immunity, relieving cough, eliminating phlegm, stopping vomit, resisting inflammation, relieving pain, resisting oxidation, resisting virus, etc [11] . The Chinese pharmacopoeia (2005 edition supplement) carrying patchouli oil is aromatic, pungent and warm, enters spleen, stomach and lung meridians, has the effects of eliminating turbid pathogen with aromatics, regulating the middle warmer and relieving vomiting, releasing exterior syndrome and relieving exterior syndrome, and corresponds to the effects of the medicinal materials.
Atractylodes lancea (Atractylodes lancea Lancea (thunb.) DC. Or Atractylodes chinensis Koidz (DC.).]It is recorded in Shen nong Ben Cao Jing (Shen nong's herbal), pungent, bitter and warm in nature. It enters spleen, stomach and liver meridians. Has the effects of eliminating dampness, strengthening spleen, dispelling pathogenic wind, dispelling cold, and improving eyesight. Can be used for treating damp obstruction of middle warmer, abdominal distention, diarrhea, edema, tinea pedis, atrophy 36484, rheumatalgia, wind cold, night blindness, dim eyesight, and eye dryness. The book Shen nong Ben Cao Jing says: cang Zhu is indicated for arthralgia due to wind-cold-dampness, spasm and jaundice. "(elephant of medication act): to say that: can remove dampness and induce sweating, invigorate stomach and strengthen spleen, and is an essential drug for curing flaccidity. It has the functions of removing filth, eliminating dampness, strengthening stomach and invigorating spleen. The compendium of materia Medica records: the Chinese medicine has the advantages of strong smell, aromatic smell, capacity of removing filth, and multiple purposes for treating diseases caused by epidemic diseases due to abnormal qi in four seasons, and is used for removing filth and drying dampness in ancient times. Its flavor is pungent and bitter with the action of dispersing the dryness, and it is also indicated for various syndromes of dampness pathogen in exterior, and it can dispel dampness and sweat to disperse pathogen in Ben Cao gang mu. The book Ben Cao Zheng Yi (Chinese materia Medica): the Chinese atractylodes has strong smell, is more vigorous than the white atractylodes rhizome, can eliminate dampness and phlegm retention, has fragrance and avoids filthy, surpasses qi which is not normal in four seasons, has multiple purposes of epidemic diseases, can most dispel filthy and foul qi, has 82308230, has the symptoms of dampness encumbering spleen yang, tiredness and addiction to bed, soreness of limbs, fullness and stuffiness in chest and diaphragm, and has 82308230and does not cause the invasion. The formula adopts the atractylodes oil as the medicine, and the oil has obvious bacteriostatic activity [12-14] It is basically corresponding to herbs in action.
Patchouli, herba Pogostemonis, pungent in flavor and warm in nature, is fragrant and can resolve dampness, rhizoma Atractylodis, pungent in flavor and warm in nature, can dry dampness and dispel cold, the two herbs are combined together to ventilate lung qi and invigorate spleen to resolve turbidity, and are monarch herbs together.
4.2 ministerial drug analysis
Elsholtzia (Mosla chinensis maxim. Or elsholtzia chinensis 'jiangxianggru') is pungent in nature and slightly warm in taste. It enters lung and stomach meridians. Has the effects of inducing sweat, relieving exterior syndrome, eliminating dampness and regulating the middle warmer. Can be used for treating summer-heat-dampness type common cold, aversion to cold, fever, and headacheNo sweating, abdominal pain, vomiting and diarrhea, edema, dysuria. It is indicated for mild cases of cholera due to cold, as recorded in Ben Cao Zheng Yi (Zheng Yi Sheng): for cholera, abdominal pain and vomiting, it is indicated for 8230that, it is 8230and Xiang Ru can unblock yang qi. "compendium" year: for cholera, it is indicated to be used to send yang-qi, disperse water and spleen. "Zhang shan Lei (materia Medica) carries it: "pay more attention to scattering exterior and to make more guidance". Similar to cang Zhu, ben Cao Yan Yi Bu Yi (supplement and relic of materia Medica) and Ben Cao Hui Yan (Collection of materia Medica) all carry out the effect of thoroughly going up and thoroughly going down, the clear qi is transformed into the qi and the heat is accumulated from the lower part when the lung is got, the turbid qi is not dry and the water channel is popular when the spleen is got, and the effect of dispersing exterior dampness of cang Zhu can be enhanced. The prescription uses elsholtzia oil as a medicine, and the oil has the functions of relieving fever, easing pain, calming, strengthening immunity, resisting bacteria, resisting virus, reducing blood pressure, reducing cholesterol, promoting urination, relieving cough, eliminating phlegm and the like [15] It is basically corresponding to herbs in action.
Folium artemisiae argyi (Artemisia artemia argyi L. Et vant.) is pungent, bitter and warm in nature; has little toxicity. It enters liver, spleen and kidney meridians. Has the effects of warming channels, stopping bleeding, removing blood stasis and relieving pain; it can dispel dampness and relieve itching for external use. Can be used for treating hematemesis, epistaxis, metrorrhagia, menorrhagia, fetal leakage, lower blood, lower abdomen psychroalgia, menoxenia, and infertility due to cold womb; it can be used for external treatment of skin pruritus. Taking the effects of warming channels, dispelling cold, relieving pain and eliminating dampness in the formula is carried in Ben Cao gang mu: "warm in the middle, cool and remove dampness". "and" Yi Lin Du Yao, property of medicine "carry it: dryness of spleen earth, nourishing stomach and qi, warming middle energizer and dispelling cold, strengthening kidney and strengthening life gate, nourishing yang and expelling yin. "dietotherapy Bencao" and "Bencao Zhengyi" have the actions of treating cholera and miasma which are closely related to cold and dampness, and stopping pain caused by exogenous pathogens, and "you Luo 2400909yan Bencao" carried it can cure sore throat and heat accumulation due to obstruction of the throat. The formula adopts the argy wormwood leaf oil as a medicine, the oil has the effects of preventing and treating cardiovascular system, central nervous system, blood coagulation, blood platelet and the like, and also has the effects of resisting bacteria, enhancing the phagocytic function of reticuloendothelial cells, relieving asthma, resisting anaphylactic shock, relieving cough, eliminating phlegm, benefiting gallbladder, exciting uterus and the like, and the Chinese pharmacopoeia (1977) carries the functional main treatment corresponding to the medicinal material of argy wormwood leaf.
Clove (Eugenia caryophyllata thunb.) is pungent in nature and warm in taste. It enters spleen, stomach, lung and kidney meridians. Has the functions of warming the middle-jiao, lowering the adverse flow of qi, tonifying the kidney and supporting yang. Can be used for treating spleen deficiency, singultus emesis, anorexia, vomiting, diarrhea, heart and stomach psychroalgia, and sexual impotence due to kidney deficiency. Clove, named as Kaibao Ben Cao, warms the spleen and stomach to relieve cholera, swelling and wind-toxicity. It also has the effects of purging lung-cold and dispelling pathogenic wind and dampness (Ben Cao Yuan Ming bud (materia Medica Du Yao). The clove oil is used as a medicine, has the effects of treating digestive system, gastric secretion and experimental gastric ulcer, and also has the effects of relieving diarrhea, benefiting gallbladder, easing pain, resisting anoxia, resisting coagulation, resisting mutation, inhibiting bacteria and killing insects and the like. Clove oil carried in the book of Standard drug and vitamin medicine of Ministry of health, has effects of nourishing viscera, tranquilizing mind, eliminating phlegm, and removing toxic substances of third-level cold-property medicine (such as opium). Can be used for treating asthma, expectoration, halitosis, pleuritis, etc. It can be applied topically to treat cold pain, numbness of limbs, chilblain, and paralysis due to brain and spinal cord diseases. The clove oil is pungent, sweet and hot in flavor and is carried in the Fujian province Chinese medicinal material standard (2006 edition) and the Guizhou province Chinese medicinal material national medicinal material quality standard (2003 edition). It enters spleen, stomach and kidney meridians. Warm stomach, check adverse rise of qi, warm kidney, alleviate pain. Can be used for treating stomach cold and distending pain, singultus, vomiting and diarrhea, arthralgia, hernia pain and toothache, and has corresponding effects to the medicinal materials.
Peppermint (Mentha haplocalyx briq.) is pungent in nature and cool in taste. It enters lung and liver meridians. Has the functions of dispelling wind and heat, clearing head and eyes, relieving sore throat, promoting eruption, soothing liver and promoting qi circulation. Can be used for treating wind-heat type common cold, early stage of wind-warm syndrome, headache, conjunctival congestion, pharyngitis, aphtha, rubella, measles, and chest and hypochondrium distention. "compendium of materia Medica": its pungent property can disperse and clear, so it is specially indicated for wind-dispelling and heat-dissipating \8230, 8230, headache, wind-evil in the head, eyes, throat and mouth and teeth, infantile convulsion, scrofula, sore and scabies. "Yao Hua Yi" can also "direct the herbs to enter nutrient and defense to dispel qi stagnation". The formula adopts peppermint oil as medicine, the oil has the effects of treating central nervous system, cardiovascular system, respiratory system and the like, and also has the effects of relieving spasm, protecting liver and gallbladder, resisting early pregnancy and uterus, resisting inflammation, promoting transdermal absorption, resisting microorganisms and the like [15] The Chinese materia medica carries its pungent taste and cool nature. Has effects of dispelling pathogenic wind and clearing heat. Can be used for treating wind-heat common cold, headache, conjunctival congestion, pharyngalgia, toothache, and skin pruritus. Its efficacy is corresponding to the herbs.
The Chinese mosla herb is pungent and warm in flavor and the mint is pungent and cool in flavor, the Chinese mosla herb enters lung channel, the dispersing and resuscitation effects are strong, the folium artemisiae argyi and the clove are pungent and warm in flavor and enter spleen, the middle-jiao and the clove are warm in flavor and dispel cold and resolve dampness, and the four medicines are used as ministerial medicines to assist the force of monarch medicines.
4.3 adjuvant drug analysis
Natural borneol is pungent, bitter and slightly cold in nature. It enters heart, spleen and lung meridians. Has the functions of inducing resuscitation, refreshing mind, clearing heat and relieving pain. Can be used for treating fever unconsciousness, convulsion, apoplexy with phlegm syncope, qi stagnation with sudden syncope, coma, heart obstruction, chest pain, conjunctival congestion, aphtha, sore throat, and purulence in ear canal. The Chinese herbal medicines (Mongolian medicine rolls) and the Chinese herbal medicines (Tibetan medicine rolls) have remarkable curative effects on clearing heat and diminishing inflammation. Modern pharmacological research shows that the natural borneol has the effects of resisting inflammation, bacteria and fertility, and the like.
Bing pian is slightly cold and harmonizes the warm and dry property of all herbs, so it is used as an adjuvant therapy.
4.4 prescription compatibility analysis
Patchouli is pungent in flavor and warm in nature and is fragrant in flavor and capable of resolving dampness, rhizoma atractylodis is pungent and bitter in flavor and warm in nature and is capable of eliminating dampness and dispelling cold, the two medicines are combined to ventilate lung qi and invigorate spleen to resolve turbidity, and are monarch medicines together; the Chinese mosla herb is pungent and warm in flavor and cool in flavor, and all the herbs enter lung channel, the efficacy of dispersing and dredging orifices is strong, the Chinese mugwort leaves and the clove are pungent and warm in flavor and enter spleen, the middle-jiao and the clove are warm in flavor and dispel cold and resolve dampness, and the four medicines are used as ministerial medicines to assist the efficacy of monarch medicines; bing pian is slightly cold and harmonizes the warm and dry property of all herbs, so it is used as an adjuvant therapy. The medicines except the borneol are prepared into the throat spray by using the volatile oil as the medicine, and the functions of dispersing and dredging orifices, removing dirt and eliminating turbid pathogen are enhanced.
The seven medicines are combined to play the roles of eliminating turbid pathogen with aromatics and freeing orifice. In clinical application, the traditional Chinese medicine is helpful for treating light and common type and convalescent coronary pneumonia and cold or influenza, and the traditional Chinese medicine belongs to damp turbidity obstruction and stagnation of lung and spleen, and has the symptoms of nasal obstruction, watery nasal discharge, cough, chest distress, short breath, fullness, weakness, muscle ache, pharyngalgia, sweating and the like.
5. Conclusion
The mild, common and common cold and influenza of the new type of coronary pneumonia are mostly caused by the invasion of exogenous pathogenic factors into the body and affecting the dysfunction of the lung defense, which results in disharmony of the defense and the exterior and the failure of the lung to disperse and descend. The symptoms are aversion to cold, fever, nasal obstruction, nasal discharge, cough, chest distress, fullness and the like. Prolonged course of disease can lead to spleen deficiency and lung deficiency. For treatment, it is advisable to remove turbid pathogen with aromatics and dredge orifices.
The medicinal composition for treating chronic obstructive pulmonary disease and silicosis has the functions of eliminating turbid pathogen with aromatics and freeing orifice. In clinical application, the traditional Chinese medicine composition is beneficial to treating light and common type and convalescent cold or flu of novel coronary pneumonia, and the symptoms of dampness and turbidity obstruction, lung stagnation and spleen trapping in the traditional Chinese medicine include nasal obstruction, watery nasal discharge, cough, chest distress, short breath, fullness, weakness, muscle ache, pharyngalgia, sweating and the like.
Further, the feed also comprises the following raw materials in parts by weight: 8-9 parts of medium-chain triglyceride.
The invention also provides a preparation method of the medicinal composition for treating chronic obstructive pulmonary disease and silicosis, which comprises the following steps:
respectively weighing the above raw materials, pulverizing herba Agastaches, rhizoma Atractylodis, herba Moslae, folium Artemisiae Argyi, flos Caryophylli and herba Menthae, performing supercritical carbon dioxide extraction and separation to obtain herba Agastaches volatile oil, rhizoma Atractylodis volatile oil, herba Moslae volatile oil, folium Artemisiae Argyi volatile oil, flos Caryophylli volatile oil and herba Menthae volatile oil, respectively, and mixing the volatile oils with natural Borneolum to obtain the medicinal composition.
Further, the above herba Agastaches, rhizoma Atractylodis, herba Moslae, folium Artemisiae Argyi, flos Caryophylli and herba Menthae are pulverized into 20-40 mesh.
The beneficial effects of the further technical scheme are that: pulverizing to 20-40 mesh for extracting volatile oil.
Further, the extraction pressure is 20-25Mpa, the extraction temperature is 35-40 deg.C, the extraction time is 90-120min, the separation pressure is 5-8Mpa, and the separation temperature is 50-55 deg.C.
The beneficial effects of the further technical scheme are that: the precise technological parameters can extract more volatile oil.
The invention also provides the application of the medicinal composition in preparing medicaments for treating chronic obstructive pulmonary diseases and silicosis.
Furthermore, the dosage form of the medicine is spray, aerosol or nasal drops.
The beneficial effects of the further technical scheme are that: the medicine is prepared into spray, aerosol or nasal drops, which is convenient for administration and better plays the drug effect.
Further, the preparation method of the spray comprises the following steps:
adding natural Borneolum into chain triglyceride, heating at 50-60 deg.C under stirring to dissolve, cooling to room temperature, adding the medicinal composition, stirring, and packaging into nasal administration spray bottle to obtain spray;
the preparation method of the aerosol comprises the following steps:
or adding natural Borneolum into chain triglyceride, heating at 50-60 deg.C, stirring to dissolve, cooling to room temperature, adding the medicinal composition, stirring, filling into aerosol aluminum can, capping, charging nitrogen gas, and installing nasal cavity administration button to obtain aerosol;
the preparation method of the nasal drop comprises the following steps:
adding natural Borneolum into chain triglyceride, heating at 50-60 deg.C, stirring to dissolve, cooling to room temperature, adding the medicinal composition, stirring, and bottling to obtain nasal drop.
The beneficial effects of the further technical scheme are that:
further, in the above preparation method of the aerosol, nitrogen is filled until the pressure in the aerosol aluminum can is 0.8-1.0Mpa.
The beneficial effects of the further technical scheme are that: the internal pressure of the aluminum tank is controlled to ensure the atomization performance, and the particle size of the fog drops can meet the requirement.
Detailed Description
The present invention may be embodied in other specific forms without departing from the spirit or scope of the invention. Thus, the present invention is not intended to be limited to the embodiments shown herein but is to be accorded the widest scope consistent with the principles and novel features disclosed herein.
Example 1
The preparation method of the medicinal composition for treating the chronic obstructive pulmonary disease comprises the following steps:
(1) Weighing 400 g of pogostemon cablin, 900 g of rhizoma atractylodis, 500 g of elsholtzia, 1100 g of folium artemisiae argyi, 10 g of clove and 200 g of mint, 1g of natural borneol and 800 g of medium-chain triglyceride, crushing the pogostemon cablin, the rhizoma atractylodis, the elsholtzia, the folium artemisiae argyi, the clove and the mint into 20 meshes, placing the 20 meshes in a supercritical extraction extractor, performing supercritical extraction and separation by using carbon dioxide, wherein the extraction pressure is 20Mpa, the extraction temperature is 35 ℃, the extraction time is 90min, the separation pressure is 5Mpa, and the separation temperature is 50 ℃, respectively obtaining pogostemon cablin volatile oil, rhizoma atractylodis volatile oil, elsholtzia volatile oil, folium artemisiae argyi volatile oil, clove volatile oil and mint volatile oil, and mixing the obtained volatile oils to obtain a mixture;
(2) Adding natural Borneolum Syntheticum into medium chain triglyceride, heating at 50 deg.C under stirring for dissolving, cooling to room temperature, adding the mixture, adding medium chain triglyceride to make up volume to 1000ml, stirring, and bottling to obtain spray.
Example 2
A method of preparing a pharmaceutical composition for treating silicosis comprising the steps of:
(1) 1000 g of patchouli, 1800 g of rhizoma atractylodis, 1200 g of elsholtzia, 2200 g of folium artemisiae argyi, 150 g of clove and 700 g of mint, 0.110 g of natural borneol and 800 g of medium-chain triglyceride are weighed. Pulverizing herba Agastaches, rhizoma Atractylodis, herba Moslae, folium Artemisiae Argyi, flos Caryophylli and herba Menthae to 20 mesh, placing in supercritical extraction apparatus, performing carbon dioxide supercritical extraction and separation at 22Mpa and 38 deg.C for 110min and 7Mpa and 52 deg.C to obtain herba Agastaches volatile oil, rhizoma Atractylodis volatile oil, herba Moslae volatile oil, folium Artemisiae Argyi volatile oil, flos Caryophylli volatile oil and herba Menthae volatile oil, respectively, and mixing the obtained volatile oils to obtain mixture;
(2) Adding natural Borneolum Syntheticum into medium chain triglyceride, heating at 55 deg.C under stirring for dissolving, cooling to room temperature, adding the medicinal composition, adding medium chain triglyceride to 1000ml, stirring, filling into an aluminum aerosol can, capping, introducing nitrogen gas until the pressure in the aluminum aerosol can is 0.9Mpa, and installing nasal cavity administration button to obtain the aerosol.
Example 3
The preparation method of the medicinal composition for treating the chronic obstructive pulmonary disease comprises the following steps:
(1) 1400 g of patchouli, 2800 g of rhizoma atractylodis, 1800 g of elsholtzia, 3300 g of folium artemisiae argyi, 300 g of clove and 1000 g of mint, 0.220 g of natural borneol and 900 g of medium-chain triglyceride are weighed. Pulverizing herba Agastaches, rhizoma Atractylodis, herba Moslae, folium Artemisiae Argyi, flos Caryophylli and herba Menthae into 20 mesh, placing in supercritical extraction apparatus, performing carbon dioxide supercritical extraction at 25Mpa and 40 deg.C for 120min, separating at 8Mpa and 55 deg.C to obtain herba Agastaches volatile oil, rhizoma Atractylodis volatile oil, herba Moslae volatile oil, folium Artemisiae Argyi volatile oil, flos Caryophylli volatile oil and herba Menthae volatile oil, respectively, and mixing the obtained volatile oils to obtain mixture;
(2) Adding natural Borneolum Syntheticum into chain triglyceride, heating at 60 deg.C, stirring to dissolve, cooling to room temperature, adding the medicinal composition, adding medium chain triglyceride to make up volume to 1000ml, stirring, and bottling to obtain nasal drop.
Effect test
1 Experimental method
1.1 preparation of model of Chronic Obstructive Pulmonary Disease (COPD)
The COPD rat model is prepared by carrying out adaptive feeding on 72 SPF rats with the weight of 250 +/-20 g and half of male and female rats for 3d, carrying out free diet and water feeding on 60 rats randomly with the half of male and female rats and adopting an intratracheal injection lipopolysaccharide method and cigarette smoking. After fasting for 12h on the 1 st day, anesthetizing the rat with 10% chloral hydrate, fixing on a laboratory bench, disinfecting the neck skin with iodine tincture, deiodinating with ethanol, separating layer by layer, exposing the trachea, lifting the head of the rat, injecting lipopolysaccharide (1 g/L) into the trachea with a 2mL injector, erecting the rat, uniformly distributing the medicine on the two lungs, sewing the neck skin, disinfecting the operation wound, and after the rat is awake, placing the rat in a cage, and freely drinking and eating. Lipopolysaccharide was injected again 1 time on day 20, as above. From the beginning of modeling, rats passively smoke 10 times multiplied by 1 time in a smoke box every day (except for 1,20 days), smoke 5 times respectively in the morning and afternoon, and knock the box wall 1 time every 5-10 min, so that the phenomenon that the rats are choked, trampled or the smoke volume is uneven to influence the experimental result due to piling is avoided.
1.2 grouping and administration
The successfully molded 60 COPD rats were randomly divided into 5 groups by weight, which were a model control group, a spray low dose group (37 mg/kg) of example 1, a spray low dose group (74 mg/kg) of example 1, a spray low dose group (148 mg/kg) of example 1 and a dexamethasone group (0.09 mg/kg), and 12 rats were taken as normal control groups. The corresponding drugs are administered to each administration group by intragastric administration of 10mL/kg, and pure water with the same volume is administered to the normal control group and the model control group by intragastric administration for 1 time per day and 30 days.
1.3 specimen Collection
1h after the last administration, anaesthetizing rat chloral hydrate, sampling blood from abdominal aorta, centrifuging at 3000r/min for 15min, taking supernatant, and detecting the contents of TNF-alpha, IL-8, VEGF and IL-1 beta in rat serum. The trachea and the lung are exposed by opening the chest, alveolar lavage is carried out, alveolar lavage fluid is recovered, centrifuged at 3000r/min for 15min, supernatant fluid is taken, and the total white blood cell count, macrophage (AM) percentage, neutrophil granulocyte (PMN) percentage and Lymphocyte (LYM) percentage in the alveolar lavage fluid are detected.
Results of the experiment
TABLE 1 example 1 Effect of spray on TNF-. Alpha.and IL-8 levels in serum of COPD rats
Note: compared with the solvent control group, the preparation method has the advantages that, * P<0.05， ** P<0.01。
the results of the experiment (table 1) show: compared with a normal control group, the contents of TNF-alpha and IL-8 in the serum of the rat of the model control group are obviously increased (P is less than 0.01); compared with the model control group, the TNF-alpha and IL-8 content in the serum of rats in each group of the spray in example 1 is remarkably reduced (P <0.05 or P < 0.01).
TABLE 2Example 1 Effect of spray on VEGF and IL-1 beta levels in serum of COPD rats
Note: compared with the solvent control group, the preparation method has the advantages that, * P<0.05， ** P<0.01。
the experimental results (table 2) show: compared with a normal control group, the content of VEGF in the serum of the rat of the model control group is obviously reduced (P < 0.01), and the content of IL-1 beta is obviously increased (P < 0.01); compared with the model control group, the serum content of VEGF in rats of each group of spray of example 1 is obviously increased (P <0.05 or P < 0.01), and the content of IL-1 beta is obviously reduced (P <0.05 or P < 0.01).
Table 3 example 1 effect of spray on total white blood cell count and percentage AM in COPD rats
Note: compared with the solvent control group, the preparation method has the advantages that, * P<0.05， ** P<0.01。
table 4 example 1 effect of spray on percentage of PMN and LYM in COPD rats
Note: compared with the solvent control group, the preparation method has the advantages that, * P<0.05， ** P<0.01。
the results of the experiment (tables 3 and 4) are shown: compared with a normal control group, the total number of white blood cells, the percentage of neutrophils (PMN) and the percentage of Lymphocytes (LYM) in the alveolar lavage fluid of the rats in the model control group are all obviously increased (P < 0.01), and the percentage of macrophages (AM) is obviously reduced (P < 0.01); compared with the model control group, the total white blood cell count, the percentage of neutrophils (PMN) and the percentage of Lymphocytes (LYM) in the alveolar lavage fluid of rats in each group of the spray of the example 1 are all obviously reduced (P <0.05 or P < 0.01), and the percentage of macrophages (AM) is obviously increased (P <0.05 or P < 0.01).
Finally, under the experimental conditions and the related dosage, the spray of the example 1 can obviously improve the symptoms of chronic obstructive pulmonary disease and silicosis, and has certain therapeutic effect.
Example 2 Aerosol Effect on silicosis model rats
2 Experimental methods
2.1 animal groups
72 SPF-grade SD male rats are adaptively fed for 3d, and are randomly divided into 5 groups, namely a model control group, an aerosol low dose group (37 mg/kg) in example 2, an aerosol medium dose group (74 mg/kg) in example 2, an aerosol high dose group (148 mg/kg) in example 2 and a pirfenidone group (100 mg/kg), wherein 12 rats are taken as a normal control group.
2.2 preparation and administration of silicosis rat model
Injecting 1% sodium pentobarbital (40 mg/kg) into abdominal cavity for anesthesia, fixing the rat in supine position on the rat board, and fixing limbs and head; a disposable venous indwelling needle is used for tracheal intubation, a syringe is used for injecting 1mL of silicon dioxide dust suspension (the content of free silicon dioxide is 99 percent, the content of particles with the particle size of <5pm is more than 99 percent, and penicillin is added according to 8000U/mL before use) through the trachea at one time, and a blank control group is injected with physiological saline with the same volume. The animal is immediately rotated after injection to uniformly distribute the liquid medicine in the lung.
And (3) starting administration at 3d after the model is built, performing intragastric administration on each administration group according to 10mL/kg of corresponding medicine, performing intragastric administration on a normal control group and a model control group according to the same volume of pure water, and performing administration for 1 time every day for 40d.
2.3 index detection
1h after the last administration, rats were anesthetized with chloral hydrate, after exsanguination, the trachea and lungs were exposed by thoracotomy, the right lung was clamped with an artery, alveolar lavage was performed and alveolar lavage fluid was recovered, centrifuged at 3000r/min for 15min, and the supernatant was taken to examine the total number of leukocytes, the percentage of neutrophils (PMN) and the percentage of Lymphocytes (LYM) in the alveolar lavage fluid. Weighing about 200mg of right lung, quickly freezing in a refrigerator at-80 ℃, preparing 10% lung tissue homogenate, and detecting the contents of TNF-alpha, IL-6 and IL-1 beta in the homogenate.
Results of the experiment
TABLE 5 example 2 Effect of Aerosol on TNF-alpha and IL-6 levels in Lung tissue of Silicoverous rats
Note: compared with the control group of the model, ** P<0.01。
the results of the experiment (table 5) show: compared with a normal control group, the contents of TNF-alpha and IL-6 in the lung tissues of rats in the model control group are obviously increased (P < 0.01); compared with the model control group, the lung tissues of rats in each group of the aerosol of the example 2 have obviously reduced TNF-alpha and IL-6 contents (P < 0.01) and are dose-dependent.
TABLE 6 example 2 Effect of Aerosol on IL-1. Beta. Content in Lung tissue of Silicoverous rats
Note: compared with the control group of the model, ** P<0.01。
the results of the experiment (table 6) show: compared with a normal control group, the content of IL-1 beta in the lung tissue of the rat in the model control group is obviously increased (P < 0.01); compared with the model control group, the IL-1 beta content in the lung tissue of rats in each group of the aerosol of the example 2 is remarkably reduced (the mean P is less than 0.01) and is in a certain dose dependence.
TABLE 7 example 2 Effect of Aerosol on the Total white blood cell count in Silicopulmonary rats
Note: compared with the model control group, ** P<0.01。
the results of the experiment (Table 7) show: the total number of white blood cells in alveolar lavage fluid of rats in the model control group is obviously increased compared with that of a normal control group (P < 0.01); the total number of leukocytes in alveolar lavage fluid of rats in each group of the aerosol of example 2 was significantly reduced compared to the model control group (mean P < 0.01).
TABLE 8 example 2 Effect of Aerosol on the percentage of PMN and LYM in silicosis rats
Note: compared with the control group of the model, * P<0.05， ** P<0.01。
the results of the experiment (Table 8) show: compared with a normal control group, the percentage of neutrophil granulocytes (PMN) and the percentage of Lymphocytes (LYM) in the alveolar lavage fluid of the rats of the model control group are obviously increased (P < 0.01); the percentage of neutrophils (PMN) and the percentage of Lymphocytes (LYM) in the alveolar lavage fluid of rats in each group of the aerosol of example 2 were significantly reduced (P <0.05 or P < 0.01) compared to the model control group.
Finally, under the experimental conditions and related dosage, the aerosol of the example 2 can obviously improve the symptoms of silicosis, and has certain therapeutic effect.
The embodiments described above are only a part of the embodiments of the present invention, and not all of them. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Claims (8)
1. The application of a medicinal composition for treating silicosis in preparing a medicament for treating silicosis is characterized in that the medicinal composition is prepared from the following raw materials in parts by weight:
4-14 parts of patchouli, 9-28 parts of rhizoma atractylodis, 5-18 parts of elsholtzia, 11-33 parts of folium artemisiae argyi, 0.1-3 parts of clove, 2-10 parts of mint and 0.01-0.2 part of natural borneol.
2. The use of the pharmaceutical composition for treating silicosis of claim 1 in the preparation of a medicament for treating silicosis, further comprising the following excipients in parts by weight: 8-9 parts of medium-chain triglyceride.
3. The use of a pharmaceutical composition for treating silicosis according to claim 1 in the manufacture of a medicament for treating silicosis, said pharmaceutical composition comprising the steps of:
weighing the raw materials of claim 1 or 2 respectively, pulverizing herba Pogostemonis, rhizoma Atractylodis, herba Moslae, folium Artemisiae Argyi, flos Caryophylli and herba Menthae, performing supercritical carbon dioxide extraction and separation to obtain herba Pogostemonis volatile oil, rhizoma Atractylodis volatile oil, herba Moslae volatile oil, folium Artemisiae Argyi volatile oil, flos Caryophylli volatile oil and herba Menthae volatile oil, and mixing the volatile oils with natural Borneolum Syntheticum to obtain the medicinal composition.
4. The use of a pharmaceutical composition for treating silicosis according to claim 3, wherein said Pogostemon cablin, atractylodes lancea rhizome, elsholtzia ciliata, artemisia argyi leaf, caryophylli flos and Menthae are pulverized to 20-40 mesh.
5. The use of a pharmaceutical composition for treating silicosis according to claim 3, wherein the extraction pressure is 20-25Mpa, the extraction temperature is 35-40 ℃, the extraction time is 90-120min, the separation pressure is 5-8Mpa, and the separation temperature is 50-55 ℃.
6. Use of a pharmaceutical composition according to claim 1 for the manufacture of a medicament for the treatment of silicosis, wherein said medicament is in the form of a spray, aerosol or nasal drops.
7. Use of a pharmaceutical composition according to claim 6 for the manufacture of a medicament for the treatment of silicosis, wherein said spray is prepared by:
adding natural Borneolum into chain triglyceride, heating at 50-60 deg.C under stirring to dissolve, cooling to room temperature, adding the medicinal composition, stirring, and packaging into nasal administration spray bottle to obtain spray;
the preparation method of the aerosol comprises the following steps:
or adding natural Borneolum into chain triglyceride, heating at 50-60 deg.C, stirring to dissolve, cooling to room temperature, adding the medicinal composition, stirring, filling into aerosol aluminum can, capping, charging nitrogen gas, and installing nasal cavity administration button to obtain aerosol;
the preparation method of the nasal drop comprises the following steps:
adding natural Borneolum into chain triglyceride, heating at 50-60 deg.C, stirring to dissolve, cooling to room temperature, adding the medicinal composition, stirring, and bottling to obtain nasal drop.
8. The use of a pharmaceutical composition according to claim 7 in the manufacture of a medicament for the treatment of silicosis, wherein said aerosol is prepared by charging nitrogen to an aerosol aluminum can at a pressure of 0.8 to 1.0Mpa.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111043663.8A CN113694100B (en) | 2021-09-07 | 2021-09-07 | Medicinal composition for treating chronic obstructive pulmonary disease and silicosis and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111043663.8A CN113694100B (en) | 2021-09-07 | 2021-09-07 | Medicinal composition for treating chronic obstructive pulmonary disease and silicosis and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113694100A CN113694100A (en) | 2021-11-26 |
| CN113694100B true CN113694100B (en) | 2022-12-09 |
Family
ID=78660782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111043663.8A Active CN113694100B (en) | 2021-09-07 | 2021-09-07 | Medicinal composition for treating chronic obstructive pulmonary disease and silicosis and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113694100B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114832044B (en) * | 2022-04-29 | 2022-11-11 | 云南白药集团股份有限公司 | Composition for treating oral ulcer, preparation method and pharmaceutical application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105343344A (en) * | 2015-11-25 | 2016-02-24 | 赵连祺 | Yin and lung nourishing formula for treating silicosis and preparation method |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111494469B (en) * | 2020-04-30 | 2022-03-08 | 云南白药集团股份有限公司 | Antibacterial and antiviral medicinal composition and application thereof |
| CN113577139A (en) * | 2021-09-07 | 2021-11-02 | 云南白药集团股份有限公司 | Application of plant composition in preparation of medicine for treating rhinitis |
-
2021
- 2021-09-07 CN CN202111043663.8A patent/CN113694100B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105343344A (en) * | 2015-11-25 | 2016-02-24 | 赵连祺 | Yin and lung nourishing formula for treating silicosis and preparation method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113694100A (en) | 2021-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106138360A (en) | A kind of Chinese medicine composition and preparation method thereof, application | |
| CN105560372A (en) | Traditional Chinese medicine spray for treating rhinitis and preparation method thereof | |
| CN113694100B (en) | Medicinal composition for treating chronic obstructive pulmonary disease and silicosis and application thereof | |
| CN102258751A (en) | Traditional Chinese medicine composition mint for treating melancholia, dispelling melancholy and relieving depression | |
| CN112587602B (en) | Traditional Chinese medicine composition for relieving cough and reducing sputum, extract and preparation method and application thereof | |
| CN104983968B (en) | Antipyretic traditional Chinese medicine composition and preparation method thereof | |
| CN1175885C (en) | Zibei Cough stopping granules and its preparation method | |
| CN102240341B (en) | Asthma-relieving dropping pill preparation method | |
| CN102526236B (en) | Pharmaceutical formulation for treating influenza and preparation method thereof | |
| CN108992580B (en) | Traditional Chinese medicine composition for eliminating phlegm and relieving cough and preparation method thereof | |
| CN105998475A (en) | Traditional Chinese medicine composition for treating allergic rhinitis in children and preparation method thereof | |
| CN103721147B (en) | For treating the Chinese medicine composition of chicken coccidiasis | |
| CN114470110B (en) | Anti-rhinitis traditional Chinese medicine composition with pain relieving effect | |
| CN111249381A (en) | Application of composition in preparation of medicine for preventing and treating constipation | |
| CN1248709C (en) | Chinese medicine prepn for stopping drug addiction | |
| CN105796746B (en) | Traditional Chinese medicine for preventing and treating recurrent upper respiratory tract infection | |
| CN108815329A (en) | A kind of Chinese medicine composition and preparation method thereof for treating flu | |
| CN109223956B (en) | Traditional Chinese medicine composition for treating cough and extraction method and application thereof | |
| CN118477149B (en) | Traditional Chinese medicine composition for treating pharyngitis | |
| CN111265631B (en) | Traditional Chinese medicine composition for respiratory diseases and preparation method and application thereof | |
| CN109200120B (en) | Medicine for treating spleen-kidney yang deficiency chronic cough and application thereof | |
| CN108619274B (en) | Traditional Chinese medicine composition for treating recurrent respiratory tract infection of children | |
| CN107137643B (en) | Medicinal composition for treating cough and asthma, preparation method and application thereof | |
| CN107050395B (en) | Traditional Chinese medicine sigmoid colon instillation preparation for treating infantile exogenous fever and preparation method and application thereof | |
| CN112316026A (en) | Traditional Chinese medicine volatile oil composition, preparation thereof, preparation method and application of preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |